IP Library Granted Patent US 11,484,049
Granted Patent B2
US 11,484,049 · App. 16/759,056 · Granted Nov 1, 2022

Antimycotoxin composition

Inventors: Michel Layus (Pleumeur Bodou, FR); Alexandre Brame (Rennes, FR)
Assignee: MIXSCIENCE
A23L3/3463A23K10/18A23K30/00A23K50/30A23L3/3571A23L33/135A61K35/742A61P31/10A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,484,049
App. No.
16/759,056
Granted
Nov 1, 2022
Kind
B2
Abstract

The invention relates to the use of a composition comprising at least one strain of Bacillus subtilis , for the degradation of mycotoxins.

Claims (17)

1. A method for the treatment of animals suffering from a pathology related to the ingestion of at least one mycotoxin, or the prevention of said pathologies, the method comprising a step of administering to an animal in need thereof, a composition comprising or consisting essentially of

strain NOL03,

said strain being filed with the CNCM under number CNCM I-4607.

2. The method according to claim 1 , wherein said composition comprises said strain NOL03, and at least one of the following strains,

Strain NOL01, filed with the CNCM under number CNCM I-4606,

Strain NOL02, filed with the CNCM under number CNCM I-5043, and

Strain NOL04, filed with the CNCM under number CNCM I-4608.

3. The method according to claim 1 , wherein said pathologies are related to the ingestion of at least two mycotoxins with different structures.

4. The method according to claim 1 , where wherein said composition comprises

Strain NOL03 deposited with the CNCM under number CNCM I-4607,

Strain NOL01 deposited with the CNCM under number CNCM I-4606, and

Strain NOL02 deposited with the CNCM under number CNCM I-5043.

5. The method according to claim 1 , wherein said at least one mycotoxin is chosen from aflatoxins B1, B2, M1, G1 and G2, toxin T-2, toxin HT-2, deoxynivalenol (or nivalenol), zearalenone, a fumonisin B family mycotoxin, and ochratoxin A.

6. The method according to claim 5 , wherein said fumonisin B family mycotoxin is fumonisin B1.

7. The method according to claim 3 , wherein said at least two mycotoxins comprise deoxynivalenol (DON) and a fumonisin B family mycotoxin.

8. The method according to claim 4 , wherein said at least one mycotoxin is selected from deoxynivalenol (DON) and a fumonisin B family mycotoxin.

9. The method according to claim 8 , wherein said fumonisin B family mycotoxin is fumonisin B1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2022
From: NOLIVADE
To: MIXSCIENCE
Reel/Frame 059608/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: LAYUS, MICHEL; BRAME, ALEXANDRE
To: NOLIVADE
Reel/Frame 053008/0325 →
Priority Claims (1)
FR 1771150 · Oct 31, 2017 · national
Continuity (1)
Related Publication 20200306321A1 · Oct 1, 2020